Navigation Links
ClearTrial Industry Expert to Lead Session at DIA Annual Meeting on Improving Accrual and Contract Management in Clinical Trials
Date:6/11/2009

Panel of leading biopharma executives will discuss how Earned Value Management can improve control over clinical development costs, payments, and accruals and facilitate compliance with Sarbanes-Oxley at the DIA 45th Annual Meeting in San Diego.

Chicago, IL (PRWEB) June 11, 2009 -- ClearTrial (www.cleartrial.com), a leading provider of clinical trial software for clinical trial operations planning, budgeting, and outsourcing, announced today that Kristin Lucas, Senior Director, Clinical Services, will chair a cross-functional panel of clinical finance and operations experts in discussing "Improving Accrual and Contract Management with Earned Value Management" at the DIA 45th Annual Meeting. Held at the San Diego Convention Center, June 21-25, 2009, the meeting will bring together the biggest names from industry, regulatory, and academia to discuss the issues affecting global drug discovery and development.

Given the unprecedented challenges facing biopharma companies, the ability to accurately measure the performance of clinical studies and better manage cost and schedule components is becoming even more critical. Earned Value Management (EVM), a widely accepted practice in many industries, has gained significant momentum in clinical development based on its ability to:

*Accurately calculate accruals based on when work is actually performed
*Quickly determine if studies are on budget by task, provider or resources
*Effectively track project performance and timelines to determine project health
*Facilitate compliance with Sarbanes-Oxley

Lucas brings more than 15 years of experience in the pharmaceutical and biotech industry to the meeting, with extensive experience in clinical trial budgeting and contract management. Before joining ClearTrial, she led the Financial Administration division for the Clinical Business Management department at ICOS Corporation (an Eli Lilly company), where she worked on the blockbuster drug Cialis®. At ICOS, Lucas was responsible for establishing best practices in the outsourcing, management, drafting, and negotiation of site and vendor agreements, as well as the development of a clinical budgeting/modeling application for lifecycle planning, budgeting and in-licensing opportunity assessment. Prior to ICOS, Lucas spent seven years with Genentech, where she was responsible for the negotiation, positioning, and pricing strategy for managed care contracts.

About ClearTrial®
ClearTrial® is a leading provider of clinical trial software for clinical operations planning, budgeting, and outsourcing. ClearTrial's award-winning software helps pharmaceutical, biotechnology, medical device companies, and CROs expedite the clinical development process without sacrificing quality of results. The company's software products support clinical operations, resource planning, and outsourcing departments with a single solution that promotes speed and consistency, while maintaining flexibility to handle different study requirements. For more information please visit http://www.cleartrial.com.

ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.

# # #

Read the full story at http://www.prweb.com/releases/2009/06/prweb2522694.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
2. ClearTrial Names Software Industry Veteran Michael Bruns as Chief Operating Officer
3. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
4. ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference
5. Industry Professionals Get Schooled in Real-World Oncology Issues at NCCN Academy
6. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
7. Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry
8. Microtest Laboratories is an Industry Leader in ICH Stability Testing
9. MichBio Leader Cites New Senate Biosciences Task Force and House Subcommittee as Evidence of States Growing Awareness of Industrys Economic Importance
10. Sugarcane Ethanol Industry Eager to Implement U.S. Renewable Fuel Standard
11. Industry Expert Reveals Cutting Edge Biotechnology Science for Nutraceutical and Functional Food Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... has been appointed Vice President, Preclinical Safety and Senior Director, Safety Pharmacology. ... Madras in India. , Dr. Thomas’ career as an academic and industry ...
(Date:1/21/2017)... ... ... Nipro Corporation (Osaka, Japan) and Transonic Systems Inc. (New York, USA) announced ... and sales rights for all non-OEM Transonic products in Japan. As partners for more ... Nipro - Transonic JV is a natural next step to advance best practices and ...
(Date:1/21/2017)... , Jan. 21, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, today presented ... compound, napabucasin, at the 2017 American Society of Clinical ... Francisco . In a Phase ... agent designed to inhibit cancer stemness pathways by targeting ...
(Date:1/20/2017)... (PRWEB) , ... January 20, ... ... in Less Exposure Surgery (LES®) Technologies, announced today the next evolution in ... Pedicle Screw System platform). In contrast to the competition, SpineFrontier is focused ...
Breaking Biology Technology:
(Date:1/19/2017)... and PUNE, India , January 19, 2017 ... "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," the global ... a CAGR of 9.6% from 2016 to 2022. In 2015, Asia-Pacific ... high-level security for both public and private sectors. ... ...
(Date:1/12/2017)... , Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... DNA (ctDNA) technologies, today announced that it has signed ... and the Middle East ...  This milestone marks the first wave of international distribution ... urine and blood samples. The initial partners ...
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
Breaking Biology News(10 mins):